D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
Trevi Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $6 to $9
Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.
D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
Trevi Therapeutics Analyst Ratings
Optimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial Results
Oppenheimer Remains a Buy on Trevi Therapeutics (TRVI)
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
Trevi Therapeutics Is Maintained at Buy by D. Boral Capital
Trevi Therapeutics Price Target Maintained With a $21.00/Share by D. Boral Capital
Trevi Therapeutics Analyst Ratings
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
Trevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Prospects and Upcoming Data Milestones
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $8
Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton